J 2016

Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants

ČEŠKOVÁ, Eva

Basic information

Original name

Current pharmacotherapy of depression - focused on multimodal/multifunctional antidepressants

Authors

Edition

EXPERT OPINION ON PHARMACOTHERAPY, Abingdon, TAYLOR & FRANCIS LTD, 2016, 1465-6566

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.894

Organization unit

Central European Institute of Technology

DOI

UT WoS

000384401200001

Keywords in English

Depressive disorder; pharmacoresistance; multimodal; multifunctional antidepressants; pharmacogenomic tests

Tags

Změněno: 24/10/2016 14:42, Mgr. Eva Špillingová

Abstract

V originále

Major depressive disorder (MDD) is a widespread disease, with a lifetime prevalence of 15% and an annual incidence of approximately 7%. It is associated with significant costs in quality of life, loss of work productivity, and a high risk of mortality. It is predicted to become the leading cause of disability in Western countries by 2030.

Links

LQ1601, research and development project
Name: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR